SLC2A11

Across TCGA pan-cancer cohorts, SLC2A11 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLC2A11 data layer compared with 21 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher SLC2A11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC2A11 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

DLBC, ESCA, and LIHC are the cancer types where SLC2A11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
ESCA	OS	Median	II,III,IV	0.226	0.686	.013	12	view →
LIHC	OS	Median	All	0.154	0.690	<.001	12	view →
SARC	DFS	Median	All	0.069	0.632	<.001	6	view →
SKCM	OS	Median	II,III,IV	0.451	0.739	.042	3	view →
UCEC	DFS	Median	II,III,IV	1.000	0.444	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SLC2A11–DLBC (OS)

Open the DLBC breakdown →